Infertility refers to the inability to conceive a child naturally after a period of regular unprotected sexual intercourse. Globally, infertility is a widely prevalent issue with societal and health implications. Global infertility drugs market growth is driven by increasing incidence of infertility among both men and women. Risk factors like rising stress levels, lifestyle changes, obesity, sexually transmitted diseases, and genetic abnormalities have contributed to growing prevalence of both male and female infertility. Advancements in assisted reproductive technologies and increasing success rates of infertility treatment procedures have provided hope to millions of struggling couples. Several pharmaceutical companies offer a wide range of infertility medications that can treat ovulation disorders, hormonal imbalances, and other fertility-related issues.

Market Dynamics:

Global infertility drugs market growth is driven by factors such as rising infertility rates, increasing prevalence of gynecological disorders, growing awareness about infertility and treatment options, rising healthcare expenditure, technological advancements in fertility treatment procedures, and the financial assistance provided by governments and other organizations. However, factors such as high cost of infertility treatment, complications and risk associated with infertility therapy, stringent regulatory framework, and cultural and social barriers in some nations can hamper the market growth. Growing number of fertility and IVF clinics across developing regions can offer lucrative growth opportunities. Emerging economies offer significant growth potential due to increasing medical tourism and favorable regulations.

Key Features of the Study:

- This report provides in-depth analysis of the global infertility drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year

- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

- It profiles key players in the global infertility drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies

- Key companies covered as a part of this study include Merck, Ferring Pharmaceuticals, LIVZON Pharmaceutical Group Inc., AbbVie Inc., and MSD

- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

- Global infertility drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global infertility drugs market

Detailed Segmentation-

• By Drug Type
  
  • Clomiphene citrate
  • Sex hormones
  • Gonadotropins
  • Bromocriptine
  • Cabergoline
  • Imipramine
  • Letrozole
  • Metformin
    
• By Gender
• • Male
  • Female
• By Distribution Channel
• • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
•   By Region         
• • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
• • Merck & Co., Inc.
  • Ferring Pharmaceuticals
  • Pharma Mar, S.A.
  • Novartis AG
  • Pfizer, Inc.
  • Takeda Pharmaceutical Company Limited
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • LIVZON Pharmaceutical Group Inc.
  • Fairfax EggBank, Inc.
  • Genea Limited
  • Cook Medical Inc.
  • Vitrolife
  • Thermo Fisher Scientific, Inc.
  • CooperSurgical, Inc.
  • Monash IVF Group
  • Finox Biotech (Finox AG)